Last reviewed · How we verify

Levobupivacaine plus sufentanil epidural infusion

University of Genova · FDA-approved active Small molecule

Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation, delivered together via epidural infusion for pain management.

Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that enhances analgesia through mu-receptor activation, delivered together via epidural infusion for pain management. Used for Epidural analgesia for postoperative pain management, Labor pain management, Chronic pain management via epidural infusion.

At a glance

Generic nameLevobupivacaine plus sufentanil epidural infusion
SponsorUniversity of Genova
Drug classLocal anesthetic + opioid combination
TargetVoltage-gated sodium channels (levobupivacaine); mu-opioid receptor (sufentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine, a local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing action potential propagation and sensory/motor blockade. Sufentanil is a potent synthetic opioid that binds mu-opioid receptors in the central and peripheral nervous system to produce analgesia. The combination provides synergistic pain relief through dual mechanisms: local conduction blockade and systemic opioid analgesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: